Objective: Study of severe visceral damage in systemic scleroderma in the rheumatology Department of CHU de Cocody. Patients and Methods: We conducted a retrospective descriptive study of the records of patients hospitalised for systemic scleroderma according to ACR/EULAR 2013 criteria in the rheumatology Department of CHU de Cocody over an 11-year period from January 1, 2005 to December 31, 2016. Results: A total of 18 patients had systemic scleroderma, 10 of whom had severe visceral damage with a frequency of 55.5%. All patients were female. The mean age was 34.5 ± 15.4 years. The mean duration of the disease was 3.5 ± 4.1 years. Clinically, 7 patients (70%) had a dry cough, 5 (50%) had stage dyspnoea and 2 (20%) had palpitations. Serious damage was pulmonary, cardiac and digestive in 8 patients (80%), 4 patients (40%) and 3 patients (30%) respectively. Pulmonary damage was mainly a combination of pulmonary arterial hypertension and interstitial lung disease in 5 patients (62.5%). Cardiac damage was represented by pericarditis in 3 patients (75%). Gastro-oesophageal reflux disease occurred in 2 patients (66.7%). Biologically, anti-nuclear antibodies were positive in all patients, Anti-Scl-70 in 44.4% and anti-centromeres in 22.2%. The course was marked by 3 deaths due to cardiovascular failure. Conclusion: Severe visceral damage is common in systemic scleroderma, dominated by cardiac and pulmonary attacks.
References
[1]
Mouthon, L., Allanore, Y., Cabane, J. and Hachulla, E. (2008) Sclérodermie systémique. In: Guillevin, L., Meyer, O. and Sibilia, J., Eds., Maladies et syndromes systémiques, Flammarion Médecine-Sciences, 410-470.
[2]
Le Guern, V. (2004) Prevalence of Systemic Sclerosis in a French Multi-Ethnic County. Rheumatology, 43, 1129-1137. https://doi.org/10.1093/rheumatology/keh253
[3]
El Adssi, H., Cirstea, D., Virion, J.M., Guillemin, F. and de Korwin, J.D. (2013) Estimating the Prevalence of Systemic Sclerosis in the Lorraine Region, France, by the Capture-Recapture Method. Seminars in Arthritis and Rheumatism, 42, 530-538. https://doi.org/10.1016/j.semarthrit.2012.10.001
[4]
Meyer, A., Chifflot, H., Chatelus, E., Kleinmann, J.F., Ronde‐Ousteau, C., Klein, D., et al. (2016) Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast Region. Arthritis & Rheumatology, 68, 1731-1737. https://doi.org/10.1002/art.39613
[5]
Arnett, F.C., Cho, M., Chatterjee, S., Aguilar, M.B., Reveille, J.D. and Mayes, M.D. (2001) Familial Occurrence Frequencies and Relative Risks for Systemic Sclerosis (Scleroderma) in Three United States Cohorts. Arthritis & Rheumatism, 44, 1359-1362. https://doi.org/10.1002/1529-0131(200106)44:6<1359::aid-art228>3.0.co;2-s
[6]
Erzer, J.N., Jaeger, V.K., Tikly, M. and Walker, U.A. (2020) Systemic Sclerosis in Sub-Saharan Africa: A Systematic Review. Pan African Medical Journal, 22, Article 176.
[7]
Denton, C.P. and Khanna, D. (2017) Systemic Sclerosis. The Lancet, 390, 1685-1699. https://doi.org/10.1016/s0140-6736(17)30933-9
[8]
Rubio-Rivas, M., Royo, C., Simeón, C.P., Corbella, X. and Fonollosa, V. (2014) Mortality and Survival in Systemic Sclerosis: Systematic Review and Meta-Analysis. Seminars in Arthritis and Rheumatism, 44, 208-219. https://doi.org/10.1016/j.semarthrit.2014.05.010
[9]
Dire, Z., Ickinger, C. and Tikly, M. (2023) Causes and Predictors of Mortality in South Africans with Systemic Sclerosis. Rheumatology & Autoimmunity, 3, 108-114. https://doi.org/10.1002/rai2.12080
[10]
Steen, V.D. and Medsger Jr., T.A. (2000) Severe Organ Involvement in Systemic Sclerosis with Diffuse Scleroderma. Arthritis & Rheumatology, 43, 2437-2444.
[11]
Illovi, C. and Oyoo, G. (2013) Characteristics of Systemic Sclerosis Patients in Nairobi, Kenya: A Retrospective Study. African Journal of Rheumatology, 1, 23-27.
[12]
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., etal. (2013) 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis & Rheumatism, 65, 2737-2747. https://doi.org/10.1002/art.38098
[13]
LeRoy, E.C. and Medsger Jr., T.A. (2001) Criteria for the Classification of Early Systemic Sclerosis. The Journal of Rheumatology, 28, 1573-1576.
[14]
Hachulla, E., Launay, D., de Groote, P., Moranne, O., Tillie-Leblond, I., Seguy, D., etal. (2005) Les défaillances viscérales graves de la sclérodermie systémique. Réanimation, 14, 576-586. https://doi.org/10.1016/j.reaurg.2005.09.019
[15]
Lindor, K.D., Gershwin, E.M., Poupon, R., Kaplan, M., Bergasa, N.V. and Heathcote, J.E. (2009) Primary Biliary Cirrhosis. Hepatology, 50, 291-308. https://doi.org/10.1002/hep.22906
[16]
Teclessou, J.N., Saka, B., Akakpo, S.A., Matakloe, H., Mouhari-Toure, A., Kombate, K., et al. (2018) Les connectivites en milieu hospitalier à Lomé: Étude rétrospective de 231 cas. Pan African Medical Journal, 30, Article 176. https://doi.org/10.11604/pamj.2018.30.176.14565
[17]
Adelowo, O.O. and Oguntona, S. (2009) Scleroderma (Systemic Sclerosis) among Nigerians. Clinical Rheumatology, 28, 1121-1125. https://doi.org/10.1007/s10067-009-1191-2
[18]
Kane, B.S., Ndongo, S., Ndiaye, A.A., Djiba, B., Niasse, M., Diack, N., et al. (2016) Maladies systémiques en médecine interne “contexte Africain”: Aspects épidémiologiques et classification. La Revue de Médecine Interne, 37, A37. https://doi.org/10.1016/j.revmed.2016.04.237
[19]
Tiendrébéogo, J.W.S., Kaboré, F., Sougué, C., Sankara, V., Zongo, E., Savadogo, B., etal. (2022) Epidemiology of Rheumatic Diseases: A Cohort of 23,550 Patients in Rheumatology Clinics in Burkina Faso. Clinical Rheumatology, 42, 371-376. https://doi.org/10.1007/s10067-022-06470-y
[20]
Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E. and Sibilia, J. (2008) Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review. Seminars in Arthritis and Rheumatism, 37, 223-235. https://doi.org/10.1016/j.semarthrit.2007.05.003
[21]
Laing, T.J., Gillespie, B.W., Toth, M.B., Mayes, M.D., Gallavan, R.H., Burns, C.J., etal. (1997) Racial Differences in Scleroderma among Women in Michigan. Arthritis & Rheumatism, 40, 734-742. https://doi.org/10.1002/art.1780400421
[22]
Steen, V., Domsic, R.T., Lucas, M., Fertig, N. and Medsger, Jr. (2012) A Clinical and Serologic Comparison of African American and Caucasian Patients with Systemic Sclerosis. Arthritis & Rheumatism, 64, 2986-2994. https://doi.org/10.1002/art.34482
[23]
Yacoub, Y.I., Amine, B., Laatiris, A., Wafki, F., Znat, F. and Hajjaj-Hassouni, N. (2012) Bone Density in Moroccan Women with Systemic Scleroderma and Its Relationships with Disease-Related Parameters and Vitamin D Status. Rheumatology International, 32, 3143-3148. https://doi.org/10.1007/s00296-011-2150-1
[24]
Ben Salah, R., Frikha, F., Hachicha, H., Chabchoub, I., Dammak, C., Snoussi, M., etal. (2019) Clinical and Serological Profile of Systemic Sclerosis in Tunisia: A Retrospective Observational Study. La Presse Médicale, 48, e284-e291. https://doi.org/10.1016/j.lpm.2019.07.037
[25]
Yen, E.Y., Singh, D.R. and Singh, R.R. (2021) Trends in Systemic Sclerosis Mortality over Forty-Eight Years, 1968-2015: A US Population-Based Study. Arthritis Care & Research, 73, 1502-1510. https://doi.org/10.1002/acr.24411
[26]
Tikly, M., Rands, A., McHugh, N., Wordsworth, P. and Welsh, K. (2004) Human Leukocyte Antigen Class II Associations with Systemic Sclerosis in South Africans. Tissue Antigens, 63, 487-490. https://doi.org/10.1111/j.0001-2815.2004.00199.x
